Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activating mutations of c-kit at codon 816 confer drug resistance in human leukemia cells.

Leukemia & lymphoma - 1 May 2001

Ning Z Q, Li J, Arceci R J

Abstract excerpt

An improved understanding of how leukemia cells grow and become resistant to treatment remains critical for developing more effective therapies. We have identified activating mutations of c-kit at codon 816 (Asp(816) ) from a revertant of the cytokine-dependent acute myeloid leukemia (AML) cell line, MO7e (D816H), and de novo childhood AML (D816N). Following transduction of the mutant c-kit cDNAs, MO7e cells...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Leukemia
Share to Mice, Inbred NOD
Share to Mice, SCID

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Transplantation

Share to Proto-Oncogene Proteins c-kit

Share to Stem Cell Factor

Share to Transduction, Genetic

Share to Transplantation, Heterologous

Source

Identifiers

PMID: 11378569
DOI: 10.3109/10428190109060342

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activating mutations of c-kit at codon 816 confer drug resistance in human leukemia cells.PMID 11378569Read ↗

Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells.Semantic proximity Read ↗

The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.Semantic proximity Read ↗

C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice.Semantic proximity Read ↗

Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate.Semantic proximity Read ↗

KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survivalSemantic proximity Read ↗

Development and Biological Evaluation of Potent and Selective c-KIT<sup>D816V</sup> InhibitorsSemantic proximity Read ↗

Cytogenetically normal acute myeloid leukemia with a novel KIT mutation in exon 11 G565V developing a sole trisomy 13 at relapse: a clinical dilemma.Semantic proximity Read ↗

AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec.Semantic proximity Read ↗

Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycinSemantic proximity Read ↗

Activating c-KIT mutations confer oncogenic cooperativity and rescue RUNX1/ETO-induced DNA damage and apoptosis in human primary CD34+ hematopoietic progenitors.Semantic proximity Read ↗

Pediatric acute myeloid leukemia with t(8;21) and KIT mutation treatment with avapritinib post-stem cell transplantation: a case reportSemantic proximity Read ↗

Pediatric acute myeloid leukemia with t(8;21) and KIT mutation treatment with avapritinib post-stem cell transplantation: a report of four cases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.